Bis[2-(pyridin-2-yldisulfanyl)ethyl] carbonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Bis[2-(pyridin-2-yldisulfanyl)ethyl] carbonate
• 英文别名: bis[2-(pyridin-2-yldisulfanyl)ethyl] carbonate
• 化学式: C₁₅H₁₆N₂O₃S₄
• 分子量: 400.6
• InChiKey: FYJDHLGGYQKENL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  163
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• [EN] CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR ANTICANCER THERAPIES<br/>[FR] CONJUGUÉS DE LA SOUS-UNITÉ B DE TOXINE DE SHIGA POUR DES THÉRAPIES ANTICANCÉREUSES
  申请人：INST CURIE

  公开号：WO2014086952A1

  公开（公告）日：2014-06-12

  Conjugates or pharmaceutical compositions comprising conjugates of the B-subunit of Shiga toxin that are useful for cancer therapies are disclosed. More specifically, the pharmaceutical compositions comprise STxB conjugated to at least one antimitotic agent such as auristatin or pharmaceutically acceptable salts thereof through a bifunctional linker. Processes to make the conjugates, as well as methods to treat cancers are also disclosed.

  披露了用于癌症治疗的志贺毒素B亚单位偶联物或药物组合物。更具体地说，药物组合物包含通过双功能连接剂与至少一种抗有丝分裂剂如auristatin或药用可接受盐偶联的STxB。还披露了制造偶联物的方法以及治疗癌症的方法。
• [EN] FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS<br/>[FR] LIGANDS DE PROTÉINE D'ACTIVATION DES FIBROBLASTES POUR APPLICATIONS D'ADMINISTRATION CIBLÉE
  申请人：PHILOCHEM AG

  公开号：WO2021160825A1

  公开（公告）日：2021-08-19

  The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.

  本发明涉及纤维母细胞活化蛋白（FAP）的配体，用于在疾病部位主动传递各种有效载荷（例如细胞毒药物、放射性核素、荧光染料、蛋白质和免疫调节剂）。具体而言，本发明涉及开发用于靶向应用的FAP配体，特别是用于诊断方法和/或与疾病或疾病相关的治疗或手术方法，如癌症、炎症或另一种以FAP过表达为特征的疾病。
• [EN] POLYMERIC CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYMÈRES ET LEURS UTILISATIONS
  申请人：FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIG PRINCIPE FELIPE

  公开号：WO2020193802A1

  公开（公告）日：2020-10-01

  The present invention relates to novel chemical entities comprising a polymeric carrier incorporating covalently linked drug(s) as well as their pharmaceutical compositions containing the said polymer-drug conjugates as pharmaceutical agents and their uses thereof in therapy and, more particularly, but not exclusively, to novel conjugates having attached thereto a targeting moiety, an imaging agent and one or more therapeutic agents to promote axonal growth and for the treatment of neurodegenerative and inflammatory diseases, central nervous system traumatic injuries and cancer.

  本发明涉及一种新型化学实体，包括将药物共价连接到聚合载体中的药物，以及包含所述聚合物-药物共轭物作为药物代理的药物组合物，以及它们在治疗中的用途，更具体地说，但不限于，涉及附有靶向基团、成像剂和一个或多个治疗剂的新型共轭物，用于促进轴突生长和治疗神经退行性和炎症性疾病、中枢神经系统创伤性损伤和癌症。
• [EN] DESIGN AND EFFICIENT SYNTHESIS OF LIPID-FLUORESCEIN CONJUGATES FOR CAR-T CELL THERAPY<br/>[FR] CONCEPTION ET SYNTHÈSE EFFICACE DE CONJUGUÉS LIPIDE-FLUORESCÉINE POUR THÉRAPIE PAR CELLULE CAR-T
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2021007109A1

  公开（公告）日：2021-01-14

  The disclosure relates to lipid-fluorescein conjugates, compositions comprising same, and methods of synthesis and use, such as in the treatment of cancer.

  该披露涉及脂质-荧光素共轭物、包含相同物质的组合物，以及合成和使用方法，例如在癌症治疗中的应用。
• FUSION PROTEIN COMPRISING GLUTATHIONE-S-TRANSFERASE AND PROTEIN HAVING BINDING AFFINITY TARGET CELL OR TARGET PROTEIN, AND USE THEREOF
  申请人：UNIST (Ulsan National Institute of Science and Technology)

  公开号：EP3718540A1

  公开（公告）日：2020-10-07

  Provided are a fusion protein including glutathione-S-transferase and a protein having binding affinity for a target cell or a target protein, and use thereof as a drug delivery carrier and a pharmaceutical composition. The fusion protein and the drug delivery carrier including the same according to an aspect may sustain an in vivo residence time, and may also have improved target cell-targeting ability, and thus may be effectively delivered to target cells. Accordingly, it may be usefully applied to a targeted therapeutic agent.

  本发明提供了一种融合蛋白，其中包括谷胱甘肽-S-转移酶和一种对靶细胞或靶蛋白具有结合亲和力的蛋白，以及将其用作给药载体和药物组合物的方法。根据一个方面，融合蛋白和药物递送载体（包括相同的融合蛋白和药物递送载体）可维持体内停留时间，还可提高靶细胞靶向能力，从而可有效地递送至靶细胞。因此，它可以有效地应用于靶向治疗剂。